Compare Adaptive Biotechnologies Corp (ADPT) vs Baker Hughes Co (BKR) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Adaptive Biotechnologies Corp vs Baker Hughes Co — how do they compare? Adaptive Biotechnologies Corp trades at $20.19 (market cap $3.33B), while Baker Hughes Co trades at $57.58 (market cap $54.04B). The key difference: Baker Hughes Co is far larger — about 16.2× Adaptive Biotechnologies Corp's market cap, and Baker Hughes Co pays a 1.69% dividend while Adaptive Biotechnologies Corp pays none. Which is the better fit depends on your goals.
| ADPT | BKR | |
|---|---|---|
Market Cap | $3.33B | $54.04B |
Sector | Health | Energy |
52-Week High | $22.37 | $69.67 |
52-Week Low | $10.24 | $38.68 |
Enterprise Value | $3.19B | $55.44B |
Dividend Yield | — | 1.69% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADPT trades at $20.82, down 1.75% today, with a bullish technical signal from moving averages and a consensus analyst price target of $20.40. The company announced a strategic separation of its MRD and Immune Medicine businesses in June 2026, alongside a $300 million convertible notes offering to enhance financial flexibility. Revenue grew to $277 million in 2025, though net losses persist at -$59.50 million, with improving margins and cash flow trends showing net positive cash generation of $22.37 million.
Outlook remains cautiously optimistic as the business split aims to unlock value, but execution risks and sustained profitability challenges pose headwinds. Analysts are predominantly bullish (64.71% buy ratings), citing growth in the clonoSEQ MRD segment, yet the stock faces volatility from high valuation multiples and insider selling activity.
Baker Hughes (BKR) trades at $54.47, up 3.2% over the past 24 hours, with a bearish technical signal from moving averages but bullish oscillators. The company has consistently beaten earnings estimates in recent quarters, with Q2 2026 results expected soon. Recent contract wins in Angola and Nigeria, along with expansion into geothermal energy, highlight growth initiatives. Financials show strong profitability with an 11.17% net income margin and improving cash flow trends, though revenue growth has moderated.
The outlook for BKR is positive, supported by analyst consensus with a $74.27 price target and 66.7% buy ratings. Key opportunities include energy transition projects and international contracts, while risks involve oil price volatility and integration challenges from the Chart Industries acquisition. The stock presents a value opportunity with a P/E of 17.01, trading below analyst targets amid operational strength.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Adaptive Biotechnologies Corp
Adaptive Biotechnologies Corp is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers.
Read more on ADPT →About Baker Hughes Co
Baker Hughes is a global leader in oilfield services and oilfield equipment, with particularly strong presences in the artificial lift, specialty chemicals, and completions markets. The other half of its business focuses on industrial power generation, process solutions, and industrial asset management, with high exposure to the liquid natural gas market specifically, as well as broader industrials end markets.
Read more on BKR →
